Caring for every patient: Day-One matters

Visit us at booth # 24103 and find out how QIAGEN can help you provide patient access to genomic testing at day-one of drug approval

Personalized approaches to patient treatment are revolutionizing cancer care. However, ensuring that your targeted therapies reach the right patient at the right time to achieve real-world impact requires precision diagnostics to match.

Our Oncology and Precision Diagnostics (OPDx) team work closely with pharma and CLIA laboratory partners to facilitate accelerated patient access to new treatments and ensure testing availability.

As your single point of contact for CDx development, we offer complete Sample to Insight solutions with integrated and highly automated workflows, simplifying validation and routine operation. Our broad portfolio of technology solutions mean we are can provide molecular CDx tests that meet your clinical trial program requirements and timelines, while our Day-One Lab Readiness program ensures global patient access to your genomic test upon drug approval in molecular labs.

Meet the QIAGEN OPDx team at booth # 24103 to learn more about our state of the art immuno-oncology collaborations. Chat with our team and find out how our targeted mutation detection, NGS, and gene expression analysis companion diagnostic expertise can help make your clinical programs more successful.

Visit us at the 2019 ASCO Annual Meeting, Booth # 24103

Social Sharing